canakinumab   

GtoPdb Ligand ID: 6773

Synonyms: ACZ 885 | ACZ885 | Ilaris®
canakinumab is an approved drug (FDA (2009), EMA (2009))
Compound class: Antibody
Comment: Canakinumab targets interleukin-1β [1].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Immunopharmacology Comments
IL-1β in cardiovascular disease: Canakinumab was the first anti-inflammatory agent to exhibit efficacy as a treatment for atherosclerosis. Results from the CANTOS trial (NCT01327846) showed that canakinumab (in high-risk patients; in addition to standard-of-care therapy) reduced the number of recurrent cardiovascular events that were recorded at 3-4 years follow-up [5-6]. These results confirmed that disruption of the IL-1β inflammatory pathway was a valid therapeutic modality for cadiovascular disease prevention. It is informative to note that the largest reduction in cardiovascular mortality was observed in those patients who achieved the greatest reduction in the circulating inflammatory mediators IL-6 and CRP, which points to the importance of employing informed patient stratification in future studies.
Immunopharmacology Disease
Disease X-Refs Comment References
Muckle-Wells syndrome OMIM: 191900
Orphanet: ORPHA575
An anti-IL-1β therapeutic approved for Muckle-Wells syndrome.
Juvenile idiopathic arthritis- systemic OMIM: 604302
An anti-IL-1β therapeutic approved for sJIA. 7
Familial cold autoinflammatory syndrome 1; FCAS1 OMIM: 120100
Orphanet: ORPHA47045
An anti-IL-1β therapeutic approved for FCAS1. 4